Harrow reaffirmed its 2025 revenue guidance of $270–280 million and outlined an aggressive commercial ramp across its ophthalmology portfolio. The company plans to double the Vevye sales force by Memorial Day, expand Iheezo beyond retina into the office-based procedure market, and double the surgical team behind Triesence. It also launched a single-brand operating model under “oneHarrow,” promoted Patrick Sullivan to chief commercial officer, advanced NDA-enabling work for MELT-300 and MELT-210 with a MELT-300 filing targeted for the first half of 2027, and resolved regulatory matters tied to its ImprimisRx division while exiting California compounding operations.
The through-line is strategic consolidation and scale. Harrow is moving decisively from a two-track business—branded medicines and compounding—toward a unified, procedure-centric platform built on payer access and field execution. The near-term bet is clear: recent coverage progress for Vevye, including an alignment with the largest U.S. commercial PBM that took effect January 1, 2026, can support heavier promotion without destabilizing net pricing. In dry eye, where clinical differentiation is subtle and adherence is fragile, access and reach are often the decisive levers. The expansion around Triesence and the repositioning of Iheezo to target separately reimbursed, office-based procedures signal confidence that site-of-care economics are shifting in ophthalmology’s favor.
This matters now because the battlegrounds in eye care are reorganizing. For HCPs, a larger field presence and a coherent brand interface should simplify access, education, and logistics across front- and back-of-eye use cases. For payers, Harrow’s push into the estimated multi-million-procedure office market with Iheezo spotlights a growing reimbursement footprint for anesthesia and minor interventions in non-facility settings—an area where utilization controls and documentation standards are likely to tighten. For patients, broader formulary positioning for Vevye could expand treatment options in a category still defined by variable response and persistence. Competitively, incumbents across dry eye and perioperative inflammation will need to defend share against a better-capitalized detailing effort, while smaller ophthalmic biotechs may see Harrow’s model as a viable commercialization partner or exit path.
The California exit for ImprimisRx is a notable tell. State-level regulatory friction is raising the cost of doing business for compounders, nudging the market toward FDA-approved alternatives and larger, compliance-heavy platforms. Harrow’s message is that branded products will continue to serve California, but the shift underscores an industry-wide recalibration: as compounding economics come under pressure, the value of labeled, reimbursable, broadly distributed brands rises. At the same time, the MELT-300 timeline aligns with the broader move to streamline in-office cataract and minor surgical workflows, potentially reducing reliance on IV sedation and supporting staffing-constrained settings—a development that will demand robust real-world evidence to secure payer confidence and procedural adoption.
The next checkpoints are straightforward but material. Does doubling the Vevye footprint translate into sustained share gains under stable net price, and how quickly does Iheezo embed in office-based, separately reimbursed pathways with clean documentation and repeat use? Can Harrow maintain salesforce productivity as it scales and realize operating leverage from oneHarrow without eroding unit economics? By mid-2026, conversion rates, reorder velocity for Triesence, and early evidence packages supporting MELT-300 will reveal whether Harrow’s transition from a hybrid compounding-branded model to a focused ophthalmic platform is building durable advantage—or merely buying time in an increasingly competitive eye care marketplace.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
